Buscar

16/08/2023 Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances
Pinana, JL, Perez, A, Chorao, P, Guerreiro, M, Garcia-Cadenas, I, Solano, C, Martino, R, Navarro, D. Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances. Transplant Infectious Disease. 2023; DOI:10.1111/tid.14117. PMID:37585370. IF:2.600(Q2/5D).
15/08/2023 B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
Woyach, JA, Ghia, P, Byrd, JC, Ahn, IE, Moreno, C, O'Brien, SM, Jones, D, Cheung, LWK, Chong, ELZB, Kwei, K, Dean, JP, James, DF, Wiestner, A. B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. CLINICAL CANCER RESEARCH. 2023; 29(16)DOI:10.1158/1078-0432.CCR-22-3887. PMID:37314786. IF:10.400(Q1/1D).
02/08/2023 Development of an in-house bone marrow collection kit: The Catalan bone marrow transplantation group experience
Fernandez-Sojo J., Valdivia E., Esquirol A., Portos, JM, Rovira M., Suarez M., Diaz-de-Heredia C., Uria, ML, Ortí G., Ferra C., Mussetti A., Paviglianiti A., Marsal J., Badell I., Lozano M., Gomez D., Azqueta C., Martorell L., Rubio N., Garcia-Buendia A., Villa J., Carreras E., Querol S.. Development of an in-house bone marrow collection kit: The Catalan bone marrow transplantation group experience. VOX SANGUINIS. 2023; 118(9)DOI:10.1111/vox.13499. PMID:37533171. IF:1.800(Q3/7D).
20/07/2023 Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
Munir, T, Moreno, C, Owen, C, Follows, G, Benjamini, O, Janssens, A, Levin, MD, Osterborg, A, Robak, T, Simkovic, M, Stevens, D, Voloshin, S, Vorobyev, V, Yagci, M, Ysebaert, L, Qi, KQ, Qi, QY, Parisi, L, Srinivasan, S, Schuier, N, Baeten, K, Howes, A, Caces, DB, Niemann, CU, Kater, AP. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(21)DOI:10.1200/JCO.22.02283. PMID:37279408. IF:42.100(Q1/1D).